Phytocannabinoids for use in the treatment of ovarian cancer, wherein preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD)； cannabidiol acid (CBDA)； cannabigerol (CBG)； cannabigerolic acid (CBGA)； cannabigerol propyl variant (CBGV)； and tetrahydrocannabivarin (THCV) and combinations thereof. Preferably the phytocannabinoid is CBG or the combination of CBG with CBD or the combination of CBD with THCV. The phytocannabinoid may be in the form of an extract or botanical drug substance.
